| Download | - View final version: Comparative performance data for multiplex SARS-CoV-2 serological assays from a large panel of dried blood spot specimens (PDF, 2.7 MiB)
|
|---|
| DOI | Resolve DOI: https://doi.org/10.1016/j.heliyon.2022.e10270 |
|---|
| Author | Search for: Cholette, François; Search for: Fabia, Rissa; Search for: Harris, Angela; Search for: Ellis, Hannah; Search for: Cachero, KarlaORCID identifier: https://orcid.org/0000-0002-9039-3164; Search for: Schroeder, Lukas; Search for: Mesa, ChristineORCID identifier: https://orcid.org/0000-0001-8465-5474; Search for: Lacap, Philip; Search for: Arnold, CoreyORCID identifier: https://orcid.org/0000-0001-6552-6650; Search for: Galipeau, Yannick; Search for: Langlois, Marc-André; Search for: Colwill, KarenORCID identifier: https://orcid.org/0000-0002-8979-1659; Search for: Gingras, Anne-Claude; Search for: McGeer, Allison; Search for: Giles, Elizabeth; Search for: Day, Jacqueline; Search for: Osiowy, CarlaORCID identifier: https://orcid.org/0000-0002-5429-7220; Search for: Durocher, Yves1; Search for: Hankins, CatherineORCID identifier: https://orcid.org/0000-0002-1642-8592; Search for: Mazer, Bruce; Search for: Drebot, Michael; Search for: Kim, John |
|---|
| Affiliation | - National Research Council of Canada. Human Health Therapeutics
|
|---|
| Funder | Search for: Canada Foundation for Innovation |
|---|
| Format | Text, Article |
|---|
| Subject | SARS-CoV-2; Covid-19; dried blood spots; serology; immunoassays; serosurveys |
|---|
| Abstract | The extent of the COVID-19 pandemic will be better understood through serosurveys and SARS-CoV-2 antibody testing. Dried blood spot (DBS) samples will play a central role in large scale serosurveillance by simplifying biological specimen collection and transportation, especially in Canada. Direct comparative performance data on multiplex SARS-CoV-2 assays resulting from identical DBS samples are currently lacking. In our study, we aimed to provide performance data for the BioPlex 2200 SARS-CoV-2 IgG (Bio-Rad), V-PLEX SARS-CoV-2 Panel 2 IgG (MSD), and Elecsys Anti-SARS-CoV-2 (Roche) commercial assays, as well as for two highly scalable in-house assays (University of Ottawa and Mount Sinai Hospital protocols) to assess their suitability for DBS-based SARS-CoV-2 DBS serosurveillance. These assays were evaluated against identical panels of DBS samples collected from convalescent COVID-19 patients (n = 97) and individuals undergoing routine sexually transmitted and bloodborne infection (STBBI) testing prior to the COVID-19 pandemic (n = 90). Our findings suggest that several assays are suitable for serosurveillance (sensitivity >97% and specificity >98%). In contrast to other reports, we did not observe an improvement in performance using multiple antigen consensus-based rules to establish overall seropositivity. This may be due to our DBS panel which consisted of samples collected from convalescent COVID-19 patients with significant anti-spike, -receptor binding domain (RBD), and -nucleocapsid antibody titers. This study demonstrates that biological specimens collected as DBS coupled with one of several readily available assays are useful for large-scale COVID-19 serosurveillance. |
|---|
| Publication date | 2022-08-28 |
|---|
| Publisher | Elsevier |
|---|
| Licence | |
|---|
| In | |
|---|
| Language | English |
|---|
| Peer reviewed | Yes |
|---|
| Identifier | S2405844022015584 |
|---|
| Export citation | Export as RIS |
|---|
| Report a correction | Report a correction (opens in a new tab) |
|---|
| Record identifier | bc2882dc-9dff-4298-8e91-a7996502b335 |
|---|
| Record created | 2023-10-26 |
|---|
| Record modified | 2023-10-26 |
|---|
